BETTER HEALTH FOR BETTER FUTURE
Learn moreOur Company
About Us
MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications.
Our Mission
Revolutionize the way we attack serious human diseases all of which are often associated with aging.
Lead Indication
MASH
Oxy210, an orally bioavailable oxysterol-based drug candidate with antifibrotic and anti-inflammatory properties, is being developed as a safe and effective treatment for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH).
